These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18498916)

  • 61. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
    Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.
    Almeida S; Filipe A; Neves R; Spínola AC; Tanguay M; Ortuño J; Farré A; Torns A
    Clin Ther; 2010 Mar; 32(3):556-74. PubMed ID: 20399993
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
    Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
    Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
    Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
    Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.
    Pillans PI; Rigby RJ; Kubler P; Willis C; Salm P; Tett SE; Taylor PJ
    Clin Biochem; 2001 Feb; 34(1):77-81. PubMed ID: 11239520
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function.
    Wigger M; Armstrong VW; Shipkova M; Wacke R; Nizze H; Streit F; von Ahsen N; Muscheites J; Glasenapp S; Stolpe HJ; Oellerich M
    Ther Drug Monit; 2002 Jun; 24(3):438-43. PubMed ID: 12021639
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial.
    Sunderland A; Russ G; Sallustio B; Cervelli M; Joyce D; Ooi E; Jeffrey G; Boudville N; Chakera A; Dogra G; Chan D; Wong G; Lim WH
    Nephrol Dial Transplant; 2020 Jun; 35(6):1060-1070. PubMed ID: 32516810
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients.
    Woillard JB; Saint-Marcoux F; Monchaud C; Youdarène R; Pouche L; Marquet P
    Pharmacol Res; 2015 Sep; 99():308-15. PubMed ID: 26192348
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation.
    Baraldo M; Cojutti PG; Isola M; Feruglio MT; Tursi V; Livi U; Furlanut M
    Transplant Proc; 2009 Dec; 41(10):4277-84. PubMed ID: 20005384
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients].
    Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M
    Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD
    Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts.
    Filler G; Lampe D; Mai I; Strehlau J; Ehrich JH
    Transpl Int; 1998; 11 Suppl 1():S82-5. PubMed ID: 9664950
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.